login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CYTOMX THERAPEUTICS INC (CTMX) Stock News
USA
-
Nasdaq
- NASDAQ:CTMX -
US23284F1057
-
Common Stock
3.84
USD
+0.03 (+0.79%)
Last: 12/3/2025, 12:46:28 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CTMX Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics to Present at Upcoming December Investor Conferences
20 days ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
a month ago - By: Zacks Investment Research
- Mentions:
WVE
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
a month ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Benzinga
- Mentions:
STVN
PODD
AMRK
SOLV
...
Earnings Scheduled For November 6, 2025
a month ago - By: Benzinga
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
a month ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
a month ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
a month ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
2 months ago - By: The Motley Fool
Why CytomX Therapeutics Stock Was Skyrocketing This Week
4 months ago - By: The Motley Fool
CytomX (CTMX) Q2 Revenue Drops 26%
4 months ago - By: Zacks Investment Research
- Mentions:
OCS
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2
4 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
6 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
7 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
7 months ago - By: Stocktwits
CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug
Please enable JavaScript to continue using this application.